Compare
Sinovac Biotech Ltd vs Lifevantage Corp vs Phibro Animal Health Corp vs Siga Technologies Inc
| Latest fiscal year | Sinovac Biotech Ltd SVA | Lifevantage Corp LFVN | Phibro Animal Health Corp PAHC | Siga Technologies Inc SIGA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2026-06-30 | 2025-12-31 |
| Revenue | $386.01M | $182.59M | $1.52B | $94.57M |
| Revenue growth (YoY) | +6.8% | -20.1% | +17.1% | -31.8% |
| Gross margin | 67.9% | 77.6% | 33.8% | 68.6% (computed) |
| Operating margin | -127.0% | 3.3% | 12.8% | 25.1% |
| Net margin | -51.5% | 2.8% | 6.6% | 24.6% |
| Net income | -$198.84M | $5.07M | $99.72M | $23.28M |
| EPS (Diluted) | -$0.83 | $0.40 | $2.43 | $0.32 |
| Operating cash flow | -$512.18M | $10.24M | $68.95M | $43.47M |
| Free cash flow | -$561.10M | $6.67M | $9.87M | n/a |
| Cash & equivalents | $488.25M | n/a | $61.42M | $154.97M |
| Total assets | $8.54B | $62.11M | $1.50B | $219.47M |
| Total liabilities | $2.15B | $28.52M | $1.12B | $20.65M |
| Shareholders' equity | $6.40B | $33.59M | $385.48M | $198.82M |
| Return on year-end equity | -3.1% | 15.1% | 25.9% | 11.7% |
| Shares outstanding | 71.86M | 12.52M | n/a | 71.61M |
Revenue, most recent five fiscal years
| Fiscal year | Sinovac Biotech Ltd | Lifevantage Corp | Phibro Animal Health Corp | Siga Technologies Inc |
|---|---|---|---|---|
| Latest | $386.01M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $1.52B Ended 2026-06-30 | $94.57M Ended 2025-12-31 |
| 1 year earlier | $361.37M Ended 2024-12-31 | $228.53M Ended 2025-06-30 | $1.30B Ended 2025-06-30 | $138.72M Ended 2024-12-31 |
| 2 years earlier | $470.17M Ended 2023-12-31 | $200.16M Ended 2024-06-30 | $1.02B Ended 2024-06-30 | $139.92M Ended 2023-12-31 |
| 3 years earlier | $1.47B Ended 2022-12-31 | $213.40M Ended 2023-06-30 | $977.89M Ended 2023-06-30 | $110.78M Ended 2022-12-31 |
| 4 years earlier | $19.37B Ended 2021-12-31 | $206.36M Ended 2022-06-30 | $942.26M Ended 2022-06-30 | $133.67M Ended 2021-12-31 |